Viewing Study NCT01383603


Ignite Creation Date: 2025-12-24 @ 7:10 PM
Ignite Modification Date: 2025-12-31 @ 1:33 AM
Study NCT ID: NCT01383603
Status: COMPLETED
Last Update Posted: 2014-06-11
First Post: 2011-06-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Sponsor: Circassia Limited
Organization:

Study Overview

Official Title: Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Status: COMPLETED
Status Verified Date: 2014-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel, synthetic, allergen derived peptide desensitising vaccine currently being developed for treatment of cat allergy.

At present, the efficacy of immunotherapy (peptide or otherwise) can only be established at the conclusion of therapy. No reliable predictive biomarkers of clinical efficacy currently exist. Identification of surrogate biomarkers of clinical efficacy, would facilitate clinical development of peptide immunotherapy vaccines, in addition to providing an improved understanding of the underlying molecular mechanisms of efficacy, thus providing new leads for therapeutic intervention.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: